

# Janet K Coller

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6354584/janet-k-coller-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

1,913

citations

23

h-index

42

g-index

65

ext. papers

2,275

ext. citations

4.5

avg, IF

4.67

L-index

#	Paper	IF	Citations
62	Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3901-3909	3.8	3
61	Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease. <i>Journal of Cellular Physiology</i> , <b>2021</b> , 236, 877-888	7	4
60	Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation. <i>Indian Journal of Gastroenterology</i> , <b>2021</b> , 40, 5-21	1.9	5
59	Brain-Immune Interactions as the Basis of Gulf War Illness: Clinical Assessment and Deployment Profile of 1990-1991 Gulf War Veterans in the Gulf War Illness Consortium (GWIC) Multisite Case-Control Study. <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	1
58	Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability.. <i>Inflammatory Intestinal Diseases</i> , <b>2021</b> , 6, 199-209	2.5	1
57	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. <i>Integrative Cancer Therapies</i> , <b>2020</b> , 19, 1534735420928493	3	14
56	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , <b>2020</b> , 126, 4423-4431	6.4	82
55	Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1015-1020	3.8	4
54	The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2170-2175	3.8	9
53	No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1686	5.6	1
52	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 4011-4022	3.9	26
51	Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis. <i>Annals of Gastroenterology</i> , <b>2019</b> , 32, 584-592	2.2	1
50	Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 528-532	3.2	4
49	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2019</b> , 29, 9-17	1.9	5
48	The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2365-2376	7.5	25
47	Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 217-236	3.5	3
46	CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2018</b> , 123, 320-326	3.1	15

45	Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2433-2442	3.8	7
44	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 431-434	3.5	7
43	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2767-2779	6.1	27
42	Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. <i>Pain</i> , <b>2016</b> , 157, 2458-2466	8	17
41	Clinically Significant Interactions with Anti-addiction Agents <b>2016</b> , 565-577		
40	Chemotherapy-induced gut toxicity and pain: involvement of TLRs. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 2251-2258	3.9	19
39	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1376-86	6.1	72
38	Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 1233-6	3.9	14
37	CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 276-84	3.8	39
36	Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. <i>Brain, Behavior, and Immunity</i> , <b>2015</b> , 45, 245-52	16.6	18
35	Pharmacogenomics of methadone maintenance treatment. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1007-27	2.6	33
34	Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2014</b> , 945-946, 171-7	3.2	16
33	A PRIMER EXTENSION DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE IDENTIFICATION OF THREE ABCC2 GENETIC POLYMORPHISMS. <i>Journal of Liquid Chromatography and Related Technologies</i> , <b>2014</b> , 37, 1249-1256	1.3	
32	The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1264-72	4	35
31	Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 617-23	3.2	24
30	Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. <i>Pharmacology &amp; Therapeutics</i> , <b>2012</b> , 134, 219-45	13.9	131
29	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 786-94	3.8	19
28	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 835-41	3.8	18

27	Drugs against Acute and Chronic Pain <b>2012</b> , 403-428		2
26	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2012</b> , 5, 53-62	2.1	29
25	Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. <i>British Journal of Pharmacology</i> , <b>2012</b> , 165, 1319-29	8.6	64
24	Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. <i>Brain, Behavior, and Immunity</i> , <b>2011</b> , 25 Suppl 1, S155-64	16.6	63
23	Naloxone-precipitated morphine withdrawal behavior and brain IL-1 $\beta$ expression: comparison of different mouse strains. <i>Brain, Behavior, and Immunity</i> , <b>2011</b> , 25, 1223-32	16.6	47
22	OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 902-5	1.9	35
21	Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 688-93	3.2	13
20	The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 70, 844-53	3.8	38
19	Role of active metabolites in the use of opioids. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 121-39	2.8	83
18	Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 869-76	1.9	35
17	Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2009</b> , 2, 9-19	2.1	15
16	Response to No Influence of ABCB1 Haplotypes on Methadone Dosage Requirement <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 669-670	6.1	6
15	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 347-54	3.8	5
14	TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2008</b> , 107, 15-24	4.4	17
13	Pharmacogenetics of opioids. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 429-44	6.1	262
12	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 128-38	4	20
11	Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 45, 410-7	2	23
10	The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 321-5	3.8	9

9	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 682-90	6.1	124
8	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2006</b> , 832, 114-20	3.2	16
7	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2006</b> , 843, 302-9	3.2	11
6	Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 456-63	3.8	6
5	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 105-11	3.8	17
4	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 287-97	3.8	100
3	Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2003</b> , 30, 845-8	3	17
2	The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. <i>British Journal of Clinical Pharmacology</i> , <b>2002</b> , 54, 157-67	3.8	107
1	Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. <i>The Histochemical Journal</i> , <b>2001</b> , 33, 329-36		42